EUCTR2013-002405-61-DE进行中（未招募）1 期
A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 307
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects are eligible for inclusion in the study if they meet the following criteria:
- •1.= 18 years of age
- •2.Diagnosis of active CLL or SLL that meets at least one of the IWCLL 2008 criteria for requiring treatment (Binet Stage = B and/or Rai Stage = I)
- •3.Disease that has progressed during or relapsed after at least one previous CLL/SLL therapy
- •4.Not appropriate for treatment with a purine-based analogue regimen (per National Comprehensive Cancer Network [NCCN] or European Society for Medical Oncology [ESMO] guidelines), including relapse = 36 months from a purine-based chemoimmunotherapy regimen or relapse = 24 months from a purine-based monotherapy regimen
- •5.A cytogenetics or fluorescence in situ hybridization (FISH) analysis of the leukemic cells within 24 months of randomization is required to document the presence or absence of del(17p). Note: if a sample from within 24 months is not available, it should be evaluated as part of the screening laboratory evaluation to inform stratification
- •6.Measurable disease with a lymph node or tumor mass > 1.5 cm in at least one dimension as assessed by computed tomography (CT)
- •7.Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (corresponds to Karnofsky Performance Status [KPS] = 60%)
- •8.Willingness by subject to be randomized to receive either ofatumumab or duvelisib at the dose and schedule defined in the protocol
- •9.Must meet the following laboratory parameters:
- •a.Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) = 3 x upper limit of normal (ULN)
- •b.Total bilirubin = 1.5 x ULN
- •c.Serum creatinine = 2.0 x ULN
- •d.Hemoglobin = 8.0 g/dL with or without transfusion support
- •e.Platelet count = 10,000 µL with or without transfusion support
- •10.For women of childbearing potential (WCBP): negative serum ß-human chorionic gonadotropin (ßhCG) pregnancy test within 1 week before randomization (WCBP defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally post-menopausal for at least 24 consecutive months [women = 55 years] or 12 consecutive months [women > 55 years])
- •11.Willingness of male and female subjects who are not surgically sterile or postmenopausal to use medically acceptable methods of birth control from the first dose of study drug to 30 days after the last dose of duvelisib and for 12 months after last dose of ofatumumab. Sexually active men, and women using oral contraceptive pills, should also use barrier contraception
- •12.Ability to voluntarily sign consent for and adhere to the entire study visit schedule and all protocol requirements
- •13.Signed and dated institutional review board (IRB)/independent ethics committee (IEC)-approved informed consent form (ICF) before any study specific screening procedures are performed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 207
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •Subjects are to be excluded from the study if they meet any of the following criteria:
- •1.History of Richter's transformation or prolymphocytic leukemia
- •2.Autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP) that is uncontrolled or requiring > 20 mg once daily (QD) of prednisone (or equivalent) to maintain hemoglobin > 8.0 g/dL or platelets > 10,000 µL without transfusion support
- •3.Refractory to ofatumumab (defined as progression or relapse <12 months of receiving ofatumumab monotherapy or < 24 months of receiving an ofatumumab-containing regimen)
- •4.Prior allogeneic transplant (prior autologous stem cell transplant >6 months prior to study entry is permitted)
- •5.Known central nervous system (CNS) lymphoma or leukemia; subjects with symptoms of CNS disease must have a negative CT scan or negative diagnostic lumbar puncture prior to randomization
- •6.Prior exposure to a phosphoinositide-3-kinase (PI3K) inhibitor (eg, GS-1101, duvelisib) or a Bruton’s tyrosine kinase (BTK) inhibitor
- •7.Use of any of the following medications or procedures within the specified timeframe:
- •?Use of live or live attenuated vaccines within 30 days prior to randomization
- •?Chemotherapy, radiation therapy, or ablative therapy within 3 weeks of randomization
- •?Tyrosine kinase inhibitor within 7 days of randomization
- •?Other investigational therapy (not included above) within 3 weeks of randomization
- •8.Ongoing treatment with chronic immunosuppressants (eg, cyclosporine) or systemic steroids > 20 mg prednisone (or equivalent) QD
- •9.History of tuberculosis treatment within the preceding two years
- •10.Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment (defined as requiring IV antimicrobial, antifungal or antiviral agents)
- •?Subjects on antimicrobial, antifungal or antiviral prophylaxis are not specifically excluded if all other inclusion/exclusion criteria are met and there is no evidence of active infection at randomization
- •11.Human immunodeficiency virus (HIV) infection
- •12.Prior, current, or chronic hepatitis B or hepatitis C infection
- •13.History of alcohol abuse or chronic liver disease (other than metastatic disease to the liver)
- •14.Unable to receive prophylactic treatment for pneumocystis or herpes simplex virus (HSV)
- •15.Baseline QT interval corrected with Fridericia’s method (QTcF) > 480 ms (average of triplicate readings) Note: This criterion does not apply to subjects with a right or left bundle branch block (BBB)
- •16.Unstable or severe uncontrolled medical condition (eg, unstable cardiac function, unstable pulmonary condition), or any important medical illness or abnormal laboratory finding that would, in the investigator’s judgment, increase the subject’s risk while participating in this study
- •17.Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix, bladder, or prostate not requiring treatment. Subjects with previous malignancies are eligible provided that they have been disease free for =2 years
- •18.History of stroke, uns
研究者
相似试验
进行中（未招募）
1 期
Study to assess the safety and efficacy of the study drug IPI-145 in Leukaemia patients compared with OfatumumabEUCTR2013-002405-61-ITInfinity Pharmaceuticals, Inc307
进行中（未招募）
1 期
Study to assess the safety and efficacy of the study drug IPI-145/Duvelisib in Leukaemia patients compared with OfatumumabChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMedDRA version: 20.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2013-002405-61-HUVerastem, Inc319
进行中（未招募）
不适用
Study to assess the safety and efficacy of the study drug IPI-145/Duvelisib in Leukaemia patients compared with OfatumumabEUCTR2013-002405-61-LVInfinity Pharmaceuticals, Inc307
进行中（未招募）
不适用
Study to assess the safety and efficacy of the study drug IPI-145/Duvelisib in Leukaemia patients compared with OfatumumabChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMedDRA version: 18.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2013-002405-61-GRInfinity Pharmaceuticals, Inc307
进行中（未招募）
不适用
Study to assess the safety and efficacy of the study drug IPI-145 in Leukaemia patients compared with OfatumumabChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMedDRA version: 14.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2013-002405-61-ESInfinity Pharmaceuticals, Inc307